Norathyriol for Health & Longevity

Evidence Review created on 11/13/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: 1,3,6,7-Tetrahydroxyxanthone, Mangiferitin, Mangiferin Aglycone

Motivation

Norathyriol (1,3,6,7-tetrahydroxyxanthone) is a small plant compound. It forms the sugar-free core of mangiferin, the abundant compound of mango leaves, bark and peel, and gut bacteria release it from mangiferin after a mango-derived product is eaten. It attracts attention as a possible active form of mangiferin and because laboratory work has studied its actions on enzymes that govern blood sugar handling and uric acid production.

In the early 1990s, norathyriol isolated from a gentian-family plant used in traditional medicine was examined in early pharmacology experiments. Later work in cells, mice and roundworms turned to these same metabolic enzymes and to lifespan. Today it is sold only as a laboratory chemical for research, and recent work has studied how the gut bacteria of different people release it from mangiferin.

This review examines what the laboratory and animal record shows for norathyriol, how far the small human record for mangiferin carries over, which risks and drug interactions its known actions imply, and what remains unmeasured in people.

Benefits - Risks - Protocol - Conclusion

Primary research articles that examine norathyriol directly and together cover its formation, absorption, metabolic actions and longevity signals.

No content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension or Lifespan.io could be found: norathyriol is a research-grade compound with no human studies, and none of these platforms has covered it.

Grokipedia

No Grokipedia article on norathyriol exists.

Examine

No Examine article on norathyriol exists.

ConsumerLab

No ConsumerLab article on norathyriol exists.

Systematic Reviews

No systematic reviews or meta-analyses for Norathyriol were found on PubMed as of November 13, 2026.

Mechanism of Action

Norathyriol is the sugar-free core (aglycone) of mangiferin; colon bacteria cleave mangiferin’s sugar bond to release it (Sanugul 2005). Its actions come from cells and animals:

  • Insulin signalling: competitive inhibition of PTP1B (protein tyrosine phosphatase 1B, the enzyme that switches the insulin receptor off), with an IC50 (the concentration giving half the maximum effect) of 9.59 μmol/l (Ding 2014).
  • Energy sensing: activation of SIRT-1 (sirtuin 1, a nutrient-sensing enzyme) and a rise in cellular AMP (adenosine monophosphate, a low-energy signal) that phosphorylates AMPK (AMP-activated protein kinase, the cell’s fuel gauge) (Li 2018).
  • Uric acid: uncompetitive inhibition of xanthine oxidase (the enzyme that makes uric acid) (Niu 2016), plus higher kidney expression of OAT1 (organic anion transporter 1, which moves uric acid into urine) (Lin 2019).
  • Inflammation and growth signalling: blockade of cyclooxygenase and 5-lipoxygenase (the enzymes making prostaglandins and leukotrienes) (Hsu 2004), and direct binding to ERK2 (extracellular signal-regulated kinase 2, a growth-signal relay) (Li 2012).

Pharmacological properties: oral bioavailability in rats was 30.4%, with glucuronide and sulfate conjugates rather than free norathyriol dominating afterwards (Guo 2018); UGT (glucuronosyltransferase) and sulfotransferase enzymes (which tag compounds for excretion) form them. Half-life after mangiferin dosing in rats was 11.25 hours (Tian 2016). It is not selective; human half-life and tissue distribution are uncharacterized.

Competing reading: free norathyriol stayed below 3 ng/mL in rat plasma after mangiferin dosing (Tian 2016), far below the micromolar levels its targets need, so cell-level actions may not occur at reachable concentrations.

Historical Context & Evolution

Norathyriol began as a plant-chemistry finding, not a remedy. In the early 1990s Taiwanese pharmacologists isolated it from Tripterospermum lanceolatum, a gentian-family plant of traditional use, and tested it on blood vessels and platelets. It relaxed rat thoracic aorta mainly by suppressing calcium influx (Ko 1991), prolonged tail bleeding time in mice dose-dependently (Teng 1991), reduced protein leakage and the writhing response (abdominal stretching, a pain behaviour) in mice (Wang 1994), and inhibited angiotensin-I-converting enzyme (which makes the vessel-narrowing hormone angiotensin II) in a dose-dependent manner (Chen 1992). None of this led to a medicine.

Attention shifted once norathyriol was recognized as the gut-bacterial product of mangiferin, after an intestinal Bacteroides strain was shown to make it (Sanugul 2005). Because mangiferin is poorly absorbed, norathyriol became the candidate “active form” behind mangiferin’s reported metabolic effects.

From 2012 the work moved to metabolic and ageing targets: suppression of solar-ultraviolet-induced skin tumours in mice (Li 2012), insulin resistance (Ding 2014), uric acid (Niu 2016) and, from 2024, roundworm lifespan (Zhang 2024). The early vascular and platelet findings were never overturned; they were simply left behind as funding followed metabolic disease.

What has not changed is the absence of any human study of norathyriol itself. The current case rests on animal and cell data plus small trials of mangiferin, whose relevance depends on how much norathyriol an individual’s gut bacteria release, which varies widely between people (Bunt 2025).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no human outcome or validated-surrogate evidence for norathyriol at all, let alone from more than one research group.

Medium 🟩 🟩

No benefit reaches Medium: no single human trial, and no observational study with a comparison group, has measured any outcome of norathyriol intake in people.

Low 🟩

Lower blood triglycerides

Blood triglycerides and free fatty acids fell in overweight adults with high blood lipids who took mangiferin, the compound from which gut bacteria release norathyriol, for 12 weeks (Na 2015). The evidence is indirect: the parent compound was tested, not norathyriol, and conversion varies by individual.

Magnitude: triglycerides 14.4% and free fatty acids 8.4% lower than placebo at 12 weeks in the adjusted analysis (Na 2015); the trial reports percentage between-group differences without confidence intervals (CIs, the range within which the true effect likely lies), and found no change in total or LDL (low-density lipoprotein, the cholesterol carrier that builds up in artery walls) cholesterol (Na 2015).

Lower insulin resistance ⚠️ Conflicted

The insulin resistance index fell with mangiferin over 12 weeks, while fasting glucose and insulin did not change (Na 2015). In mice, norathyriol improved insulin sensitivity through PTP1B (Ding 2014). Evidence is indirect: parent compound or animals. Net reading: a small index shift with neither underlying measure moving.

Magnitude: insulin resistance index 8.4% lower than placebo at 12 weeks in the adjusted analysis (Na 2015), with no between-group difference in fasting glucose or insulin (Na 2015); no confidence intervals reported.

Sharper attention after a single dose ⚠️ Conflicted

Single doses of mango leaf extract improved attention and memory (Wightman 2020) and processing speed (Beltrán-Arranz 2026), both sponsored by extract maker Nektium Pharma; a larger PepsiCo-funded 300 mg trial found no gain (Dodd 2024). Evidence is indirect: a whole extract, not norathyriol. Net reading: an inconsistent, short-lived signal.

Magnitude: Trail Making Test B (a timed task of switching attention between number and letter sequences) completed 6.93 seconds faster than placebo 3 hours after 100 mg (95% CI 2.15 to 11.71 seconds faster) (Beltrán-Arranz 2026); no improvement in cognitive performance or mood over placebo after 300 mg (Dodd 2024).

Speculative 🟨

Lower uric acid

Norathyriol lowered serum urate dose-dependently in hyperuricaemic (high-uric-acid) mice by inhibiting xanthine oxidase (Niu 2016), and raised urate excretion in rats by raising a kidney urate transporter (Lin 2019). Rodent and in-vitro basis only.

Less liver fat

Norathyriol regulated liver fat handling more strongly than mangiferin in liver cells, via a nutrient-sensing and fuel-gauge pathway; the diabetic mice received only mangiferin (Li 2018). Cell and animal basis; no human liver-fat data.

Blunted post-meal glucose rise

Norathyriol inhibited α-glucosidase (the gut enzyme that releases glucose from starch) more potently than mangiferin, and lowered blood glucose after a carbohydrate load in diabetic mice (Shi 2017). Rodent and enzyme data only.

Longer lifespan

Norathyriol extended lifespan in the roundworm Caenorhabditis elegans by 15.9%, with insulin-like and nutrient-sensing pathways implicated (Zhang 2024). A second group reported median lifespan 13.3% longer via antioxidant responses (Chen 2026). Roundworm basis only.

Protection from ultraviolet-induced skin tumours

Applied to the skin before solar ultraviolet exposure, norathyriol suppressed skin tumour development in hairless mice by blocking a growth-signal relay (Li 2012). Mouse-only, and by a route no human study has tested.

Dampened inflammatory signalling

Norathyriol reduced white blood cell accumulation and inflammatory messenger production in mice (Wang 1994) and blocked both prostaglandin and leukotriene pathways in isolated cells (Hsu 2004). Animal and cell basis only.

Benefit-Modifying Factors

  • Gut bacterial conversion: Release of norathyriol from dietary mangiferin varies widely between people and was traced to one uncultured bacterial strain, so the same mango-derived intake yields different exposure (Bunt 2025).

  • Genetic variation in conjugating enzymes: Glucuronidation and sulfation dominate norathyriol’s fate in rats (Guo 2018), so inherited variation in UGT1A (the glucuronidation enzyme family, which attaches sugar acids to compounds for excretion) activity plausibly sets how much free compound circulates. Untested in people.

  • Baseline biomarker levels: The urate effect was shown in hyperuricaemic animals (Lin 2019) and the glucose effect in diabetic mice (Shi 2017), so benefit is less likely where urate and glucose already sit in the optimal range.

  • Sex: Norathyriol activated both estrogen receptor alpha and beta in cells, unlike mangiferin (Wilkinson 2015). Whether this produces sex-different responses in people is unknown; no animal or human study has compared the sexes.

  • Pre-existing conditions: The mangiferin lipid effect was measured in overweight patients with hyperlipidemia (elevated blood fats) (Na 2015), so metabolically healthy individuals have no corresponding evidence of benefit.

  • Age: No animal or human study of norathyriol has compared age groups. The lifespan signal comes from roundworms treated from early adulthood (Zhang 2024), which says nothing about older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human clinical endpoint or validated surrogate has ever been measured after norathyriol intake, so no replicated human adverse-event evidence exists.

Medium 🟥 🟥

No risk reaches Medium: there is no single human trial and no comparison-group observational study of norathyriol exposure.

Low 🟥

No risk reaches Low: uncontrolled human data are absent too — no case report, case series or human indirect report of harm from norathyriol has been published.

Speculative 🟨

Loss of short-chain-fatty-acid-producing gut bacteria

In cultured human faecal communities, norathyriol raised pH, reduced bacterial counts and suppressed producers of short-chain fatty acids (fibre-fermentation products that feed colon cells), including Faecalibacterium prausnitzii (Bunt 2025). Basis is laboratory fermentation, not people.

Increased bleeding tendency

Norathyriol prolonged tail bleeding time dose-dependently in mice and suppressed platelet aggregation in rat plasma (Teng 1991). Animal data only; no human bleeding outcome has been studied.

Skeletal muscle calcium release

Norathyriol released calcium from the muscle’s calcium store via the ryanodine receptor (the muscle calcium release channel), and produced weaker twitches and contracture (sustained tightening) in isolated mouse diaphragm (Kang 1996). Isolated-tissue basis only.

Blood pressure lowering

Norathyriol relaxed rat aorta by suppressing calcium entry (Ko 1991) and, as 1,3,6,7-tetrahydroxyxanthone, inhibited angiotensin-I-converting enzyme (Chen 1992). Both actions could lower blood pressure further than intended; animal and enzyme data only.

Estrogen receptor activation

Unlike mangiferin, norathyriol activated both estrogen receptor alpha and beta in a cell reporter assay and reduced breast cancer cell viability (Wilkinson 2015). Cell-culture basis; the direction of any effect in people is unknown.

Interference with clearance of other substances

Norathyriol competitively inhibited the glucuronidation enzymes UGT1A3, UGT1A7 and UGT1A9 (Sun 2017) and inhibited P-glycoprotein (a drug efflux pump) in kidney and intestinal cells (Chieli 2009). In-vitro basis only.

Risk-Modifying Factors

  • Genetic variation in conjugating enzymes: Norathyriol inhibits UGT1A3, UGT1A7 and UGT1A9 in vitro (Sun 2017); reduced-function variants of these enzymes would plausibly raise both its own exposure and that of co-ingested substances. Untested in people.

  • Gut microbiome composition: The bacterial strain that releases norathyriol from mangiferin is present in some individuals and not others (Bunt 2025), so exposure from mango-derived products, and any harm tied to it, differs between people.

  • Baseline biomarker levels: Serum urate fell in hyperuricaemic rodents (Lin 2019) and blood glucose fell after a carbohydrate load in diabetic mice (Shi 2017); where these values already sit low, the same actions carry a theoretical overshoot risk.

  • Sex: Norathyriol activated both estrogen receptors in cells (Wilkinson 2015), a mechanism whose consequences plausibly differ by sex and hormonal status. No animal or human study has compared the sexes for any adverse outcome.

  • Pre-existing conditions: Bleeding disorders, hormone-sensitive cancers and inherited muscle calcium-channel disorders are the groups flagged by prolonged bleeding time in mice (Teng 1991), estrogen receptor activation in cells (Wilkinson 2015) and muscle calcium release (Kang 1996). None has been examined in people.

  • Age: No study has examined norathyriol in aged animals or older adults. Age-related decline in kidney and liver clearance would be expected to raise exposure to its conjugates, which dominate blood levels in rats (Guo 2018).

Key Interactions & Contraindications

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Urate-lowering drugs (allopurinol, febuxostat, probenecid): inferred from norathyriol’s inhibition of xanthine oxidase and its activation of the kidney urate transporter OAT1 in rodents (Lin 2019); consequence is urate falling further than the drug alone intends; serum urate checks detect it.

  • Substrates of UGT1A3, UGT1A7 and UGT1A9 (mycophenolate, propofol, mefenamic acid): inferred from competitive inhibition of these glucuronidation enzymes in vitro (Sun 2017); consequence is higher exposure to the co-administered drug; spacing doses several hours apart limits overlap.

  • P-glycoprotein substrates (digoxin, fexofenadine, vincristine): inferred from inhibition of this efflux pump in kidney and intestinal cell lines (Chieli 2009); consequence is higher absorption and blood levels of the substrate drug; spacing doses several hours apart limits overlap.

  • Antiplatelet (blocking platelet clumping) and anticoagulant (slowing blood clotting) drugs (aspirin, clopidogrel, warfarin): inferred from antiplatelet activity in isolated platelets and prolonged bleeding time in mice (Teng 1991); consequence is additive bleeding risk; stopping 1–2 weeks before surgery limits it.

  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen): inferred from overlapping blockade of cyclooxygenase and lipoxygenase in isolated cells (Hsu 2004); consequence is additive effects on platelet function and the stomach lining; noting bruising, gum bleeding or dark stools detects it.

  • Blood-pressure-lowering drugs (lisinopril, amlodipine): inferred from relaxation of the rat aorta (Ko 1991) and inhibition of angiotensin-I-converting enzyme (Chen 1992); consequence is blood pressure dropping below target; home blood pressure readings detect it.

  • Glucose-lowering drugs (metformin, glipizide, acarbose): inferred from α-glucosidase inhibition (Shi 2017) and improved insulin signalling (Ding 2014) in rodents; consequence is low blood sugar, particularly with insulin secretagogues (drugs prompting insulin release, such as glipizide); fasting glucose checks detect it.

  • Estrogen-receptor-modulating drugs (tamoxifen, raloxifene): inferred from activation of both estrogen receptor subtypes in a cell reporter assay (Wilkinson 2015); consequence is unpredictable interference with the drug’s intended receptor effect; avoiding the combination prevents it.

  • Supplements with additive effects (berberine, fish oil, ginkgo, beetroot nitrate, garlic): inferred from the same glucose-lowering, antiplatelet and blood-vessel-relaxing mechanisms above; consequence is additive glucose lowering, bleeding tendency or blood pressure reduction; fasting glucose checks and home blood pressure readings detect it.

  • Supplements and herbs that raise exposure (Rhizoma Anemarrhenae preparations containing timosaponin B2): inferred from a 5.9-fold rise in norathyriol exposure in rats given the decoction rather than purified mangiferin (Tian 2016); consequence is amplification of every effect above; avoiding the combination prevents it.

Populations who should avoid Norathyriol:

  • Pregnant and breastfeeding women: inferred from activation of both estrogen receptors in cells and the complete absence of reproductive or developmental data (Wilkinson 2015); no human data.

  • People with a bleeding disorder, on anticoagulants, or facing surgery: inferred from prolonged bleeding time in mice and antiplatelet activity in isolated platelets (Teng 1991); no human data.

  • People with a hormone-sensitive cancer, such as estrogen-receptor-positive breast cancer: inferred from activation of estrogen receptor alpha and beta in a cell reporter assay (Wilkinson 2015); no human data.

  • People with inherited muscle calcium-channel disorders linked to RYR1 (the gene for the muscle calcium release channel), such as malignant hyperthermia susceptibility (an anaesthesia-triggered muscle reaction): inferred from calcium release through the ryanodine receptor and contracture in isolated muscle (Kang 1996); no human data.

  • Children and adolescents: inferred from the absence of any human exposure data at any age, together with the estrogen-receptor and muscle findings above; no human data.

Risk Mitigation Strategies

Parameters below without a citation reflect common practice rather than a sourced threshold, since no clinical protocol for norathyriol exists.

  • Dietary rather than isolated exposure: Mango-derived foods and mangiferin-standardized extracts deliver norathyriol only through gut bacterial conversion, which keeps free-compound levels low (Tian 2016), avoiding the untested exposure of the purified research chemical.

  • Separation from medicines: Spacing mango-derived extracts several hours from drugs cleared by glucuronidation (Sun 2017) or by P-glycoprotein (Chieli 2009) limits the overlap that raised drug exposure in vitro.

  • Platelet and bleeding awareness: Because animal data show prolonged bleeding time (Teng 1991), stopping mangiferin-standardized extracts 1–2 weeks before planned surgery or a dental procedure mitigates additive bleeding risk.

  • Urate and glucose measurement: Serum urate and fasting glucose before and 8–12 weeks after starting a mangiferin-standardized extract detect overshoot from the rodent urate (Lin 2019) and glucose (Shi 2017) effects.

  • Liver and kidney panel: A baseline and 12-week liver enzyme and creatinine panel mirrors the safety monitoring of the one controlled mangiferin trial, which found no change in these markers (Na 2015), and would catch unexpected organ stress.

  • Gut symptom tracking: Noting stool consistency and bloating addresses the suppression of short-chain-fatty-acid-producing bacteria seen in cultured human faecal communities (Bunt 2025), the only microbiome-level signal reported.

  • Avoiding concurrent additive agents: Keeping norathyriol-yielding extracts apart from other antiplatelet or blood-pressure-lowering supplements prevents additive bleeding (Teng 1991) and additive blood pressure reduction (Ko 1991).

Therapeutic Protocol

No clinical protocol for norathyriol exists; the parameters below without a citation (timing, splitting, cycling) reflect common practice for mangiferin-standardized extracts rather than sourced norathyriol values.

  • No human regimen: No practitioner protocol, guideline or trial regimen for norathyriol has been published. The compound is sold for laboratory use only, as the MedChemExpress norathyriol listing states.

  • Doses used in animals: Rodent urate studies used 0.92–3.7 mg/kg (Niu 2016) and 0.5–4.0 mg/kg (Lin 2019); the skin work applied 0.5–1 mg topically to mice (Li 2012).

  • The only human-tested route: The alternative approach is the parent compound: mangiferin 150 mg daily for 12 weeks in a placebo-controlled trial (Na 2015), with gut bacteria releasing norathyriol from it.

  • Human pharmacokinetic (absorption and clearance) references: A single oral 0.9 g mangiferin dose in healthy men peaked around one hour, with a 7.85-hour elimination half-life (Hou 2012); a 12-person mango leaf extract study also measured mangiferin exposure (Fuentes-Rios 2025).

  • Competing approach — whole-plant preparations: Rhizoma Anemarrhenae decoction raised mangiferin and norathyriol exposure 11.5-fold and 5.9-fold over purified mangiferin in rats (Tian 2016), a traditional-medicine route rather than an isolated-compound one.

  • Half-life in the body: Norathyriol’s systemic half-life was 11.25 hours in rats after mangiferin dosing (Tian 2016); no human half-life for norathyriol has been measured.

  • Single versus split dosing: The human mangiferin trial used one daily dose (Na 2015). A split schedule has not been tested; the long rodent half-life gives no reason to assume it matters.

  • Time of day: No study has compared timing. With food is the common-practice choice for mango-derived extracts, since α-glucosidase inhibition acts on starch in the meal (Shi 2017).

  • Genetic polymorphisms: Variants of UGT1A3, UGT1A7 and UGT1A9, the glucuronidation enzymes norathyriol inhibits (Sun 2017), are plausible dose modifiers, since glucuronidation dominates its fate in rats (Guo 2018). None has been tested as such.

  • Sex differences: No study has reported sex-specific dosing or response. The human mangiferin trial enrolled both sexes and adjusted for sex without reporting a separate result (Na 2015).

  • Age considerations: No dose data exist for any age group, and none for adults over 60; the human mangiferin evidence comes from middle-aged overweight adults (Na 2015).

  • Baseline biomarkers: Elevated triglycerides were the entry condition for the only controlled human evidence (Na 2015), so baseline lipids and urate define who the sparse evidence applies to.

  • Pre-existing conditions: The glucose findings came from diabetic mice (Shi 2017) and the urate findings from hyperuricaemic rodents (Lin 2019); healthy-animal and healthy-human response data are absent.

Discontinuation & Cycling

  • Lifelong versus short-term: No duration has been established. The longest human exposure to the parent compound is 12 weeks of mangiferin in a controlled trial (Na 2015); nothing supports open-ended use.

  • Withdrawal effects: None reported, for norathyriol or mangiferin. No study has followed participants or animals after stopping, so the absence of reports reflects absence of study rather than evidence of safety.

  • Tapering: No taper has been described or tested. The mechanisms involved — enzyme inhibition and transporter expression — reverse as the compound clears, which gives no pharmacological basis for tapering.

  • Cycling: Cycling has not been studied. Rodent urate effects persisted with twice-daily dosing over five doses without reported loss of effect (Niu 2016), so tolerance is undocumented either way.

Sourcing and Quality

  • Research-grade only: Norathyriol is catalogued as a research chemical, with purity stated as 99.74% and the note “For research use only. We do not sell to patients.” on the MedChemExpress norathyriol listing. No food-grade or pharmaceutical-grade supply exists.

  • No supplement product: Searches of examine.com and consumerlab.com returned no entry for norathyriol, and no finished consumer product declares it as an ingredient, so no third-party testing programme covers it.

  • The mangiferin-standardized alternative: Mango leaf extracts standardized to mangiferin are the commercial, human-tested form; the cognition trials used Zynamite (Nektium Pharma, at least 60% mangiferin) (Wightman 2020) and Zynamite S (60% mangiferin) (Beltrán-Arranz 2026), the lipid trial purified mangiferin at 150 mg daily (Na 2015).

  • What to look for in those extracts: A declared mangiferin percentage, a certificate of analysis from an independent laboratory, and heavy-metal and pesticide testing, since mango leaf and bark are agricultural materials. These are common-practice criteria, not norathyriol-specific standards.

  • Identity risk: Norathyriol shares the tetrahydroxyxanthone skeleton with isomers such as the 1,3,5,6- and 2,3,6,7- forms, isolated from the same plant (Chen 1992), so material without an identity assay cannot be assumed to be norathyriol.

  • Conversion is not controllable: Even with a well-characterized mangiferin extract, the resulting norathyriol exposure depends on an individual’s gut bacteria (Bunt 2025), so no product can specify a delivered amount.

Practical Considerations

  • Time to effect: Unknown for norathyriol. The controlled human evidence for the parent compound measured outcomes at 12 weeks (Na 2015); the rodent urate effect showed a time dependence after single dosing (Niu 2016).

  • Common pitfalls: Treating rodent findings as human doses; assuming mangiferin intake delivers a predictable amount of norathyriol (Bunt 2025); and reading the in-vitro potency figures as achievable, when free plasma levels in rats stayed below 3 ng/mL (Tian 2016).

  • Regulatory status: Norathyriol holds no US drug label on DailyMed and no entry on drugs.com, and it is not marketed as a dietary supplement ingredient; suppliers restrict it to research, as the MedChemExpress norathyriol listing states.

  • Cost and accessibility: Research-grade material is listed in sub-milligram sample sizes with prices given only on request, as the MedChemExpress norathyriol listing shows. Mangiferin-standardized mango leaf extracts are inexpensive and widely available by comparison.

Interaction with Foundational Habits

  • Sleep: None known; no interaction has been studied. The only indirect consideration is mechanistic: the targets described above lie in glucose, lipid and urate handling rather than in sleep-regulating pathways, and no trial of norathyriol or of mangiferin has measured a sleep outcome.

  • Nutrition: Direct. Gut bacteria release norathyriol from dietary mangiferin (Bunt 2025), so mango-derived foods are the only dietary route to it, and α-glucosidase inhibition acts on starch in the meal (Shi 2017), making carbohydrate-containing meals where a glucose effect would show.

  • Exercise: Potentiating in one combination and none in another, untested for norathyriol alone: mangiferin with luteolin improved sprint performance and muscle oxygen extraction in active men (Gelabert-Rebato 2019), in a study co-financed by extract maker Nektium Pharma, sponsor of a registered mango leaf trial (NCT07126717); mangiferin with quercetin left cycling performance unchanged (Mazza 2025).

  • Stress management: None shown. A single 300 mg dose of mango leaf extract had no interpretable effect on mood scales, which included stress ratings (Wightman 2020); the salivary cortisol outcomes registered for that trial (NCT04299217) have not been reported, and no norathyriol study has measured stress.

Monitoring Protocol & Defining Success

Because no human protocol exists, monitoring is built around the two mechanisms with the most consistent animal data — urate handling and glucose or lipid handling — plus the organ-safety panel used in the one controlled trial of the parent compound (Na 2015). Baseline measurement before any mango-derived or research-compound exposure establishes the individual’s own starting values, since no target range specific to norathyriol has been defined anywhere. Ongoing measurement repeats the trial’s 12-week timepoint, then follows a common-practice interval of every 6–12 months while exposure continues, with an earlier repeat if a result moves outside its reference range. Success is defined conservatively: movement of urate, triglycerides or fasting glucose from an individual’s own elevated baseline toward the reference range, with liver and kidney markers unchanged.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum uric acid 3.5–7.2 mg/dL (standard reference range) Marker the intervention is expected to change The most consistent rodent effect, via xanthine oxidase inhibition and urate excretion (Lin 2019); no fasting requirement; pairs with creatinine
Fasting glucose 70–99 mg/dL (standard reference range) Marker the intervention is expected to change 8–12 hour fast; the rodent α-glucosidase action predicts a fall (Shi 2017), although the controlled mangiferin trial found no between-group change in glucose (Na 2015)
Serum triglycerides No established target; track change from the individual’s own baseline Marker the intervention is expected to change 12 hour fast, morning draw; the only controlled human signal for the parent compound, a 14.4% between-group fall at 12 weeks (Na 2015)
ALT 7–55 U/L (standard reference range) Safety check that stops or changes use ALT is alanine aminotransferase, a liver enzyme released when liver cells are stressed; no liver-enzyme change occurred in the 12-week mangiferin trial (Na 2015); strenuous exercise in the preceding 48 hours can raise the value
Serum creatinine 0.6–1.3 mg/dL (standard reference range) Safety check that stops or changes use Kidney urate transport is a target organ action (Lin 2019); dehydration at the draw can raise the value; pairs with uric acid

Qualitative markers worth tracking alongside the laboratory values:

  • Unusual bruising, gum bleeding or prolonged bleeding from minor cuts
  • Stool consistency and bloating, given the gut-bacterial findings
  • Muscle cramping, weakness or unusual fatigue after exertion
  • Lightheadedness on standing, which would fit the blood-vessel-relaxing mechanism
  • Energy and mental clarity through the day, as a general tolerability signal

Emerging Research

  • No registered norathyriol trial: A ClinicalTrials.gov search for norathyriol returns no study, so no trial of the compound itself is recruiting, ongoing or completed anywhere in the registry.

  • Completed mango leaf extract cognition trial, results published: NCT07126717, a crossover trial in 88 university students of a single 100 mg soluble mango leaf extract dose versus placebo, completed June 2025 (sponsor Nektium Pharma); its report found faster processing, better attention and mood up to five hours (Beltrán-Arranz 2026).

  • Earlier stress and cognition trial, results published: NCT04299217 tested a single mango leaf extract dose against placebo in 75 healthy adults aged 18–45, completed March 2020; its report found better attention accuracy and episodic memory with 300 mg, and no interpretable mood effect (Wightman 2020); a later 114-person trial found no gain (Dodd 2024).

  • What would strengthen the case: A human pharmacokinetic study of norathyriol itself, establishing whether plasma levels reach the micromolar range its targets require (Ding 2014), is the missing first step; without it every benefit claim stays speculative.

  • What would weaken it: Confirmation in people of the gut-bacterial findings — fewer short-chain-fatty-acid producers and lower urate-consuming bacteria after norathyriol (Bunt 2025) — would turn a laboratory signal into a documented harm.

  • Open question on conversion: Identifying who carries the converting bacterial strain would show whether dietary mangiferin yields any meaningful norathyriol exposure in most people (Bunt 2025), the premise on which the whole field rests.

  • Derivative chemistry: Synthetic norathyriol analogues designed as stronger inhibitors of the insulin-signalling phosphatase (Xue 2019) could move the mechanism forward without the parent compound, which would make norathyriol itself a starting point rather than an intervention.

Conclusion

Norathyriol is the sugar-free core of mangiferin, the main compound of mango leaves, and it appears when gut bacteria break mangiferin down. Its appeal is simple: in animals it enters the bloodstream far more readily than mangiferin, and it acts on the enzymes that handle blood sugar, blood fats and uric acid.

The evidence falls short of that appeal. Norathyriol has never been given to people. Everything pointing to benefit comes from cells, mice, rats or roundworms: lower uric acid, better response to insulin, less liver fat, longer worm lifespan, fewer sun-driven skin tumours in mice. The closest human evidence is for mangiferin: in overweight adults with raised blood fats, blood fats fell, while total cholesterol, blood sugar and insulin did not move. Single doses of mango leaf extract gave inconsistent gains in attention.

The safety picture is just as thin, and that thinness reflects absent study rather than demonstrated safety. Nothing has been recorded in people, while laboratory work shows effects on the cells that stop bleeding, on muscle calcium handling, on hormone receptors, on the enzymes that clear other substances, and on the balance of gut bacteria. No medicines regulator or clinical guideline covers it, and it is sold only as a laboratory chemical. An extract maker funded the positive mango leaf extract studies and a beverage company the larger null one; none studied norathyriol.

Judged by evidence quality, norathyriol sits at the speculative end: a molecule with interesting laboratory actions whose human story has not started.

Top - Benefits - Risks - Protocol